Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
XSPRAY Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr23.00 - kr90.61
Previous CloseN/A
Volume2.99K
Average Volume (3M)20.31K
Market Cap
kr1.14B
Enterprise Valuekr1.36B
Total Cash (Recent Filing)kr192.85M
Total Debt (Recent Filing)kr8.28M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 07, 2025EPS Estimate
-1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.52
Shares Outstanding30,872,599
10 Day Avg. Volume18,691
30 Day Avg. Volume20,310
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr23.00 and its highest was kr90.61 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr1.14B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is May 07, 2025 which is in 12 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Feb 12, 2025. The company reported -kr2.358 earnings per share for the quarter, missing the consensus estimate of -kr1.821 by -kr0.537.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate is -1.81.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 30,872,599 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr2.358 in its last earnings report, missing expectations of -kr1.821. Following the earnings report the stock price went up 3.215%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
---
Company Description
Xspray Pharma AB
Xspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.
---
Technical Analysis
Cantargia AB
―
IRLAB Therapeutics AB Class A
―
Saniona AB
―
Xbrane Biopharma AB
―
SynAct Pharma AB
―
---